
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies is experiencing growth in its new prescribers, with Epsolay and Twyneo recording increases of 6% and 5%, respectively, indicating a strengthening market presence. The company has achieved improved managed care coverage, with a notable increase of over 1 million commercial lives covered for Epsolay, bringing the total to 67.1 million. Additionally, the recent asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. and revised revenue estimates for 2024 and 2025 highlight substantial potential for long-term growth through collaborations and market receptivity to its products.
Bears say
Sol-Gel Technologies Ltd. has experienced a significant decline in the market uptake of its key products, with total prescriptions for Twyneo decreasing by 23% in 1Q24 compared to the previous quarter, and patient refills dropping by 18%. The company's reported top-line revenue of $213,000 indicates a substantial miss against expectations, alongside concerns about continued revenue growth prospects due to challenges with gross-to-net discounting encountered by its partner, Galderma. Additionally, ongoing risks related to slow market adoption of both Twyneo and Epsolay, potential commercialization issues with Galderma, setbacks in other product developments, and possible dilution further compound the negative outlook for Sol-Gel Technologies's stock.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares